Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Intestinal epithelial membrane permeability describes the ability of the single-cell layer of the gut epithelium to selectively allow passage of nutrients, ions, and water while restricting harmful substances (toxins, pathogens, antigens)[1][2][3][4]. This property is primarily regulated by junctional complexes (tight junctions, adherens junctions, desmosomes) made up of various transmembrane and cytosolic proteins such as claudins, occludin, and zonula occludens (ZO) proteins[1][3]. Disturbance or dysregulation of these protein complexes can lead to increased intestinal permeability ("leaky gut"), which is implicated in a range of inflammatory, infectious, metabolic, and autoimmune disease processes[1][2][4]. Intestinal permeability is a regulatable property but not a defined drug target or molecule; its modulation is an emerging area of research for therapies in gastrointestinal and systemic diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Intestinal epithelial membrane permeability.